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ABSTRACT
Following a multivariant analysis we demonstrated that children and adolescents 
with Burkitt lymphoma (BL) and a 13q14.3 deletion have a significant decrease in 
event free survival (EFS) despite identical short intensive multi-agent chemotherapy. 
However, how this deletion in the 13q14.3 region is associated with a significant 
decrease in EFS in children and adolescents with BL is largely unknown. The gene 
Deleted in Lymphocytic Leukemia 1 (DLEU1) is located in the region of 13q14.3. Here, 
we report that DLEU1 expression is implicated in the regulation of BL programmed cell 
death, cell proliferation, and expression of apoptotic genes in transcription activator-
like effector nuclease (TALEN)s-induced DLEU1 knockdown and DLEU1 overexpressing 
BL cell lines. Furthermore, NSG mice xenografted with DLEU1 knockdown BL cells had 
significantly shortened survival (p < 0.05 and p < 0.005), whereas those xenografted 
with DLEU1 overexpressing BL cells had significantly improved survival (p < 0.05 and 
p < 0.0001), following treatment with rituximab and/or cyclophosphamide. These 
data suggest that DLEU1 may in part function as a tumor suppressor gene and confer 
chemoimmunotherapy resistance in children and adolescents with BL.
INTRODUCTION
Pediatric Burkitt lymphoma (BL) is the most 
common histological subtype of non-Hodgkin lymphoma 
(NHL) in children and adolescents [1, 2]. We and others 
have demonstrated that the prognosis of pediatric BL has 
remarkably improved over the past 40 years following the 
introduction of short intensive multi-agent chemotherapy 
[1–4]. However, this successful approach is limited 
by significant chemotherapy-induced acute toxicity, 
suggesting the need to identify less toxic and more targeted 
therapy [1, 2]. We investigated the addition of the anti-
CD20 monoclonal antibody, rituximab, to the FAB (French 
American British) chemotherapy regimen in children and 
adolescents with intermediate-risk and advanced BL [5, 
6]. Immunotherapy, by targeting CD20 by rituximab, has 
been demonstrated to alter a variety of signal transduction 
pathways, including NF-κB, MAPK/ERK, JAK/STAT, 
PI3K/AKT, and B-cell receptor pathways. These alterations 
lead to cell death and/or sensitization of cells to the effects 
of cytotoxic chemotherapeutic agents [7–9]. Furthermore, 
children and adolescents with BL who relapse or progress 
after initial chemoimmunotherapy have a dismal prognosis, 
suggesting the development of chemoimmunotherapy 
resistant disease [1, 2]. Novel strategies will be required 
for the reduction of both acute morbidities and prolonged 
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hospital stays secondary to intensive multi-agent 
chemotherapy in newly diagnosed patients with BL and/
or circumvention of chemoimmunotherapy resistance in 
patients with relapsed/refractory disease.
We have previously identified secondary 
chromosomal aberrations in 70% of pediatric BL patients 
with a C-MYC gene rearrangement [10]. Specifically, we 
identified a significantly inferior event free and overall 
survival (EFS and OS) in children and adolescents with a 
specific loss of the 13q14.3 locus [10, 11]. In multivariate 
analysis controlling for stage, lactate dehydrogenase 
(LDH) levels, country of treatment, and group 
classification, children and adolescents with BL who had 
a 13q deletion had significantly poorer EFS compared to 
patients treated with the same French American British 
(FAB) chemotherapy regimen [10].
We compared the molecular signature and gene 
expression profile of pediatric BL patients treated within the 
Children’s Oncology Group, National Cancer Institute, and 
Berlin-Frankfurt-Munster (BFM) - pediatric NHL Group 
[12] and found consistency in the pediatric BL molecular 
signature [12–15]. Interestingly, Dave et al. suggested 
that DLEU1 gene located at chromosome 13q14.3 region 
[16, 17] is significantly amplified in adult BL vs. diffuse 
large B-cell lymphoma (DLBCL), and is one of the BL 
molecular classifying genes and a target of the oncogene, 
C-MYC [14]. Deletion of DLEU1, therefore, may in part 
form the molecular basis for the significantly inferior EFS 
in children with BL and a concomitant 13q14.3 deletion 
when treated with FAB chemotherapy [10].
DLEU1 has been found frequently deleted and 
a potential tumor suppressor gene in hematopoietic 
tumors including chronic lymphocytic leukemia (CLL) 
and mantle cell lymphoma [16, 17]. An open reading 
frame  corresponding to a 78 amino acids sequence has 
been identified in DLEU1 gene by human transcriptome, 
functional genomics and proteomic analysis [18, 19]. DLEU1 
protein has been predicted to interact with several cancer-
related proteins, including c-Myc, Tubulin beta-2C chain 
(TUBB2C), E3 ubiquitin-protein ligase (UBR1), cellular 
tumor antigen p53, and Ras association (RalGDS/AF-6) 
domain family member 1 (RASSF1) [18]. Interestingly, 
TUBB2C and RASSF1 are frequently silenced in human 
cancers and enhance apoptosis and tumor suppression [20, 
21]. UBR1 affects the cell cycle via PI3K-AKT signaling 
and loss of UBR1 accelerates B-cell lymphomagenesis [22]. 
We have observed that the expression levels of RASSF1, 
TUBB2C and UBR1 were significantly higher in BL 
compared to DLBCL cell lines [23]. These data, taken 
together, suggest that DLEU1 may function as a tumor 
suppressor in c-Myc activated BL by repressing cell cycle 
progression and enhancing programmed cell death via 
protein-protein interaction. In the current study, we set out 
to investigate the hypothesis that the deletion of DLEU1 in 
BL may affect the expression of DLEU1 network genes and 
alter signal transduction pathways leading to the inhibition 
of programmed cell death and in part be responsible for 
the mechanism of resistance to chemoimmunotherapy in 
patients with BL with a 13q14.3 deletion.
RESULTS
Generation of TALEN mediated DLEU1 
knockdown BL cell line
Three pairs of TALENs (TALEN1, TALEN2, and 
TALEN3) targeting the endogenous DLEU1 gene were 
constructed based on modified restriction enzyme and 
ligation (REAL) assembly methods for DLEU1 gene 
modification (Figure 1A). To excise the entire DLEU1 
locus, TALEN1 and TALEN3 (T13), and TALEN2 and 
TALEN3 (T23) were transfected into Raji cells. Single 
DLEU1 knockdown Raji cell clones were screened for the 
desired 23 Kb deletion which was confirmed by PCR and 
sequencing analysis (Figure 1B). To ensure the purity of 
a single clone, one of the positive single clones (T13-2) 
was re-plated and its daughter cells, four clones T13-2-2, 
T13-2-4, T13-2-14 and T13-2-16 were re-screened as 
above. Quantitative RT-PCR showed significant reduction 
in expression of DLEU1 compared to WT, with reductions 
of 75% (p < 0.01), 80% (p < 0.05), 83% (p < 0.01), and 
77% (p < 0.01) in clones T13-2-2, T13-2-4, T13-2-14, and 
T13-2-16, respectively (Figure 1C). Since clone T13-2-14, 
hereafter referred to as “DLEU1 knockdown (DLEU1-KD)”, 
showed the highest reduction of DLEU1 mRNA, we used 
this clone for all further experimentation in this study. The 
DLEU1-KD clones had no significant reduction in DLEU2 
mRNA (data not shown).
Establishment of DLEU1 stably overexpressing 
BL cell line
DLEU1 full-length cDNA was cloned into 
pEGFP-N3 expression vector and GFP-DLEU1 plasmid 
was transfected into HEK293 cells to confirm expression 
of the fusion protein under the fluorescent microscope 
(Figure 1D and 1E). GFP-DLEU1 construct was then 
stably transfected into Raji cells. The expression of 
DLEU1 at mRNA level was detected by RT-PCR 
(Figure 1F), and the predicted size of the fusion protein 
(approximately 36 kDa) was confirmed by western 
blotting analysis (Figure 1G) whereas endogenous DLEU1 
protein was not detectable in GFP control.
DLEU1 expression levels have significant effects 
on BL cell proliferation and programmed cell 
death
To examine whether  DLEU1 gene affects cell 
proliferation and programmed cell death in BL, Raji 
cells with or without DLEU1 knocked out (DLEU1-KD 
or WT), were plated into 48-well plates and evaluated 
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Figure 1: TALENs-induced DLEU1 knockdown and DLEU1 stably overexpressing Raji cell line. (A) A diagram showing 
the targeting of the DLEU1 locus by three different TALENs and TALE repeat arrays are shown with the repeat-variable di-residue (RVD) 
underlined and represented by small colored rectangles boxes. Two monomeric TALENs (L and R) are required to bind the DLEU1 target 
site to cleave DNA by fused FokI. TSS, transcription start site. (B) Single clones with TALEN1 and 3-induced DLEU1 locus disruption 
(22,843bp deletion, boxed with red dot line) were isolated. (C) Comparison of expression of DLEU1 mRNA between WT control (WT) 
and DLEU1 knockdown single clones T13-2-2, T13-2-4, T13-2-14 and T13-2-16 by qRT-PCR. Data are presented as mean ± SD (n = 3, 
paired t test) and p-value are displayed on plot. (D) Diagram of DLEU1 gene and ORF (78 a.a). Empty GFP vector (GFP) and GFP fused 
DLEU1 (GFP-DLEU1) constructs are shown. ATG, start codon; TAG, stop codon. (E) GFP and GFP-DLEU1 fusion plasmids were stably 
transfected into Raji cells, and then western blotting (F) and qRT-PCR (G) were performed. Data are presented mean ± SD of triplicates 
(paired t test). *p < 0.005.
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every 24 hours for cell proliferation by MTS assay 
and programmed cell death by Caspase 3/7 assay. 
DLEU1-KD cells showed a significant increase in cell 
proliferation (20% at 24 hrs, p < 0.05; 25% at 48 hrs, 
p < 0.05) (Figure 2A), and a significant reduction in 
caspase 3/7 activity (25% at 24 hrs, p < 0.01; 33% at 
48 hrs, p < 0.05) (Figure 2B), when compared to those 
of WT cells. Conversely, when we overexpressed GFP or 
GFP-DLEU1 in Raji cells, GFP-DLEU1 cells showed a 
significant decrease in cell proliferation (15% reduction, 
p < 0.03; 19% reduction, p < 0.03; and 15% reduction, 
p < 0.01 at 24, 48 and 72 hours, respectively) (Figure 2C) 
and a significant increase in programmed cell death 
(10.2% increase, p < 0.02; 9.7% increase, p < 0.05 at 
24 and 48 hours, respectively) (Figure 2D) compared to 
GFP control cells.  We further analyzed the expression of 
anti- and pro-apoptotic genes in these cells, and found that 
DLEU1 knockdown resulted in a significant increase in 
expression of the anti-apoptotic genes (Bcl-2, Bcl-xL and 
Mcl-1 ), and decrease in that of the pro-apoptotic gene 
(Bax) at mRNA level (Figure 2E). Consistently, GFP-
DLEU1 expression induced a significant decrease in Mcl-1 
and increase in Bax expression (Figure 2F). We observed 
similar changes in the expression of these genes at protein 
levels (Figure 2G and 2H).
DLEU1 significantly affects the expression of 
network genes and signaling pathways in BL
To monitor the expression of DLEU1 network 
genes, TUBB2C and UBR1, in DLEU1-KD cells compared 
to WT, quantitative reverse-transcriptase PCR (qRT-PCR) 
was performed. There was significantly reduced 
expression of TUBB2C and UBR1 mRNA (60%, p < 0.05; 
25%, p < 0.01, respectively) (Figure 3A) in DLEU1-KD 
compared to WT cells. Furthermore, we compared protein 
activation related to Akt and NF-κB signaling pathways in 
DLEU1-KD and WT cells. DLEU1 knockdown resulted 
in significant increase in phosphorylation level of IκBα 
(2.6 fold, p < 0.01) and Akt (1.5 fold, p < 0.05) (Figure 3B 
and 3C). Conversely, GFP-DLEU1 expression induced 
significant inhibition of phosphorylation of IκBα (30% 
reduction, p < 0.05) and Akt (46% reduction, p < 0.05) 
(Figure 3D and 3E).
DLEU1 knockdown results in significant 
inhibition of programmed cell death, and 
increase in cell proliferation, in rituximab  
and/or cyclophosphamide treated cells
We next examined the changes in cell proliferation 
and caspase 3/7 dependent apoptosis in DLEU1-KD cells. 
These cells were treated with rituximab (RTX) (10 ug/ml) 
and cyclophosphamide (CTX) (10 mM), alone or in 
combination, for 48 hours. A significant reduction was 
noted in caspase 3/7-dependent apoptosis in DLEU1-
KD cells treated with RTX alone (15% reduction, 
p < 0.05), CTX alone (24% reduction, p < 0.05) and in 
combination (35% reduction, p < 0.05) compared to 
WT cells (Figure 4A). Conversely, a significant increase 
in cell proliferation was observed in DLEU1-KD cells 
treated with RTX alone (10% increase, p < 0.05), CTX 
alone (9.4% increase, p < 0.05) and in combination 
(7.7% increase, p < 0.05) (Figure 4B). Moreover, RTX 
treated DLEU1-KD cells showed a significant increase 
in expression of anti-apoptotic genes, Bcl-2 and Bcl-xL 
(>1.3-fold, p < 0.05 and >2.0-fold, p < 0.05, respectively), 
and a significant decrease in expression of the pro-
apoptotic gene, Bax (~25%, p < 0.05) (Figure 4C). These 
results were further confirmed at protein level by western 
blotting analyses. (Figure 4D). 
Global gene expression profiling in DLEU1 
knockdown cells
To understand and elucidate the function and 
mechanism of DLEU1 gene in BL, we took a genomic 
approach employing Affymetrix GeneChip technology in 
DLEU1-KD vs. WT cells. A total of 2,501 differentially 
expressed genes (DEGs) from 21,381 human genes 
were identified (>2-fold, p < 0.05, 11.7%) between 
TALENs-induced DLEU1-KD cells compared to WT 
cells (Figure 5A). From among the 2,501 filtered genes, 
1,995 genes (1,722 known genes plus 273 unknown 
genes, 79.8%) were up-regulated and 506 genes (415 
known genes plus 91 unknown genes, 20.2%) were 
down-regulated (Figure 5B). When DEG-associated gene 
ontology (GO) terms were assessed, 126, 26 and 29 GO 
terms were associated with up-regulated genes whereas 
78, 15 and 27 GO terms were associated with down-
regulated genes (p < 0.05) among biological process, 
cellular component, and molecular function categories, 
respectively (Figure 5C and Supplementary Table 1). 
Functional clustering results of up-regulated genes suggest 
that genes related to anti-inflammatory response and anti-
apoptotic response were activated including STAT1, IRAK1, 
ATK1, IκBα, CCNG2 and Bcl-2. Functional clustering 
results of down-regulated genes suggest that chromatin 
remodeling associated processes were inhibited. Notably, 
hematopoietic processes, especially B cell activation or 
possibly lymphoid lineage, were inhibited due to down-
regulation of cell adhesion. A selected subset of DLEU1 
target genes with biological function were validated by real 
time qRT-PCR. The results indicated a pattern consistent 
with gene expression profiling data (Figure 5D).
Effect of DLEU1 on sensitivity of xenograft 
tumors to RTX and/or CTX in vivo
We further investigated whether DLEU1 
expression level has any effect on the sensitivity to 
RTX and/or CTX treatment of xenografted NSG mice. 
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DLEU1-KD or WT Raji cells engineered to express 
luciferase were injected into NSG mice. Xenografted 
mice were then treated with RTX (30 mg/kg), CTX 
(25 mg/kg), or RTX together with CTX, weekly for 
4 weeks. Mice receiving PBS served as a vehicle 
control. We found that tumors formed by DLEU1-KD 
cells grew faster than those by WT cells under the 
treatment of RTX, CTX, or combined (Supplementary 
Figure 2), indicating that the DLEU1 knockdown cells 
were more resistant to the treatment of these drugs. 
Consistently, we found that DLEU1-KD cells injected 
mice had significantly shortened survival time compared 
Figure 2: DLEU1 downregulates cell proliferation and upregulates caspase-dependent apoptosis. (A, C) Comparison of 
DLEU1-KD vs WT (A) and GFP-DLEU1 vs GFP (C) cell proliferation. (B, D) Caspase 3/7 activity in DLEU1-KD vs WT cells (B) and 
GFP-DLEU1 vs GFP cells (D). (E–H) mRNA (E, F) and protein (G, H) expression of anti-apoptotic and pro-apoptotic genes in the Bcl-2 
family in DLEU1-KD vs WT (E, G) and GFP-DLEU1 vs GFP (F, H) cells. Data are represented as the mean ± SD of triplicates (paired 
t test). *p < 0.05; **p < 0.01.
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Figure 3: DLEU1 regulates the expression of network genes and signaling pathways. (A) mRNA expression of DLEU1 
network genes in DLEU1-KD vs WT cells. (B, C) Significant increase in p-Akt and p-IκBα levels in DLEU1-KD vs WT cells. (D, E) 
Significant decrease in p-Akt and p-IκBα levels in GFP-DLEU1 vs GFP cells. Data are represented as the mean ± SD of triplicates (paired 
t test). *p < 0.05; **p < 0.01.
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to those injected with WT cells when treated with RTX 
(42 days vs. 52 days, p < 0.005), or RTX combined with 
CTX (48 days vs 55.5 days, p < 0.05) (Figure 6A–6D). 
In the GFP-DLEU1 overexpressed xenograft model, we 
found that GFP-DLEU1 mice had significantly extended 
survival compared to GFP mice following treatment of 
RTX (57.5 days vs 51 days, p < 0.05, n = 8 per group), 
CTX (50.5 days vs 37.5 days, p < 0.0001, n = 12 per 
Figure 4: Caspase-dependent apoptosis and cell proliferation in rituximab and cyclophosphamide alone or in 
combination-treated DLEU1-KD vs WT cells. (A) Caspase 3/7 activity of rituximab (RTX, 10 ug/ml), cyclophosphamide (CTX, 
10 mM) and RTX plus CTX combination (RTX/CTX) treated DLEU1-KD vs WT cells. (B) Cell proliferation of RTX, CTX and RTX/CTX 
treated DLEU1-KD vs WT cells. (C, D) The mRNA (C) and protein (D) expression of anti-apoptotic genes in RTX treated DLEU1-KD vs 
WT cells. Data are represented as the mean ± SD of triplicates (paired t test). *p < 0.05.
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group), and RTX/CTX-combination treatment (60.5 days 
vs 53 days, p < 0.05, n = 12 per group) (Figure 6E–6H and 
Supplementary Figure 3). 
DISCUSSION 
Children and adolescents with 13q14.3 deletion have 
a significant poorer EFS compared to pediatric BL patients 
without this abnormality [10, 11]. Furthermore, this region 
has been determined to be the most frequently genetically 
altered locus in B-CLL [24, 25] and a major control 
locus of B-cell proliferation in CLL [24]. In the current 
preclinical study, we investigated if DLEU1 expression 
alters 1) BL programmed cell death, cell proliferation and 
the expression of DLEU1 network genes in vitro and 2) 
the survival of DLEU1 knockdown and overexpressing BL 
xenografted mice following chemoimmunotherapy. 
We generated TALENs-mediated DLEU1 KD 
(83% reduction, p < 0.01) as well as GFP-DLEU1 stable 
expressing Raji BL cell lines. We investigated the effect of 
DLEU1 expression on cell proliferation and programmed 
cell death, and analyzed the expression of network genes 
and signaling pathways in BL following treatment with 
RTX and/or CTX using qRT-PCR and western blotting 
analyses. Gene expression profiling was performed using 
Affymetrix microarrays in DLEU1 KD BL cells compared 
Figure 5: Gene expression patterns in DLEU1-KD vs WT. (A) Hierarchical clustering comparing the gene expression patterns 
between DLEU1-KD and WT cells. Green represents decreased expression and red increased expression, according to the scale. 
(B) Number of up- (left column) and down- (right column) regulated genes by DLEU1. (C) The numbers of genes in each functional 
category are demonstrated. (D) Verification of DLEU1 regulated genes identified by Affymetrix Genechip profiling by qRT-PCR. GAPDH 
was used as an endogenous control for normalization.
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Figure 6: Survival of DLEU1-KD and GFP-DLEU1 mice treated with rituximab, cyclophosphamide and rituximab/
cyclophosphamide combination. (A–D) Pair-wise comparison of survival curves of WT and DLEU1-KD mice (A–D) following the 
treatment of RTX, CTX, or RTX/CTX. *p < 0.05; **p < 0.005. (E–H) Pair-wise comparison of control (GFP) and DLEU1 overexpressed 
(GFP-DLEU1) xenograft mice (E–H) following the treatment of RTX, CTX, or RTX/CTX. ns, not significant; *p < 0.05; **p < 0.005; 
***p < 0.0001.
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to control to identify cellular processes regulated by 
DLEU1. We found that DLEU1 in part regulates BL 
apoptosis, cell proliferation and associated signaling 
pathways. Gene expression data additionally support the 
hypothesis that DLEU1 plays in part a role in BL cell 
signaling by demonstrating that anti-inflammatory and 
anti-apoptotic response genes, STAT1, IRAK1, ATK1, IκBα, 
CCNG2 and Bcl-2 were activated whereas hematopoietic-
associated and chromatin remodeling-associated genes 
were downregulated in DLEU1-KD BL in comparison 
to wild type BL cells. These observations are consistent 
with the recent report of tumor suppressive function within 
the genetic region of 13q14.3 which is associated with 
suppressing tumor cell viability in cancers [24]. 
Furthermore, we observed a significant decrease in 
both chemotherapeutic and immunotherapeutic responses 
of DLEU1 KD cells as compared to WT with CTX and 
RTX, respectively, suggests that a DLEU1 loss may in 
part be a potential mechanism for therapeutic resistance. 
We then established in vivo xenograft NSG mouse models 
with DLEU1 knockdown and overexpressing Raji cells 
and investigated the sensitivity of these xenograft tumors 
to the treatment of RTX and/or CTX. More importantly, 
the deletion of DLEU1 results in significant enhancement 
of tumor progression and shortened survival in RTX and 
CTX treated DLEU1 KD cells xenografted mice compared 
to WT cell injected mice. In contrast, GFP-DLEU1 
BL xenografted mice treated with RTX and/or CTX 
exhibited a significant survival advantage over control BL 
xenografted mice. These data in part suggest that DLEU1 
level is associated with chemoimmunotherapy resistance.
The use of a TALENs method provided an 
opportunity to investigate the loss of function of a specific 
gene [26–29]. While this study sheds some light on at 
least one mechanism of chemoimmunotherapy resistance 
in BL, it will be important to investigate the role of 
other gene products found in the 13q14.3 region such 
as microRNA clusters, miR-15a/miR-16-1 [24, 30], and 
long non-coding RNA (lncRNA) gene, DLEU2 [24], and 
RFP2 and/or KCNRG [31]. DLEU1 may perhaps work 
in tandem with miR-15a/miR-16-1, DLEU2 and/or RFP2 
to create an additive or synergistic tumor suppressive or 
oncogenic effect. We plan to investigate in future studies 
the individual and combined roles of miR-15a, miR-16-1, 
DLEU2 and/or RFP2 by molecular excision via TALENs 
in BL lymphomagenesis and their importance in regulating 
BL programmed cell death.
Interestingly, DLEU1 has been considered as a 
lncRNA gene [16, 17, 24]. However, DLEU1 was defined 
as putative functional protein coding gene that encodes 
a 78 amino acids based on Ensemle database [32] and 
the universal protein resource (UniProt) [33, 34]. It has 
recently been implicated that predicted open reading 
frame in lncRNA can be translated to functional peptides 
[35, 36]. A human protein-protein interaction study 
showed an interaction between DLEU1 and TUBB2C, 
TUBB2C and Bruton’s tyrosine kinase (BTK) [37, 38], 
suggesting that DLEU1 may interact with BTK. BTK 
is a regulator of normal B-cell development and is 
activated upon B-cell receptor (BCR) stimulation [39]. In 
addition, BTK has recently become an important target 
in hematological malignancies, with the development of 
various targeted therapies specifically targeted to inhibit 
BCR signaling [40, 41].  Specifically, a BTK-targeting 
molecule, ibrutinib has been approved by FDA for 
treatment of CLL and MCL patients who have failed prior 
therapy and is currently under pre-clinical investigation 
for treatment of BL [42]. We aim to further investigate 
the potential connection between DLEU1 and the BCR 
signaling pathways, and the role of this relationship in BL.
In summary, our results suggest that the deletion 
of DLEU1 at 13q14.3 in BL may in part result in 
chemoimmunotherapy resistance in BL. Furthermore, 
there is also the implication for pretreatment screening 
for the presence of the 13q14.3 deletion in children and 
adolescent BL and the potential investigation of alternative 
therapeutic strategies. In future studies, we will address 
which therapies may perhaps re-sensitize BL cells 




Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and according to national and international 
guidelines and has been approved by the Institutional 
Animal Care and Use Committee at New York Medical 
College.
Engineering of transcription activator-like 
effector nucleases (TALENs) targeting DLEU1
Potential TALENs target sites of DLEU1 were 
identified using web-based ZiFiT Targeter software 
(http://zifit.partners.org/). The BLAST analysis and 
Repeat Masker Web server (www.repeatmasker.org) 
were utilized for uniqueness of targeted sequences. 
The designed DLEU1 TALEN pairs were constructed 
based on Restriction Enzyme And Ligation (REAL) 
assembly methods using the Joung Lab REAL Assembly 
TALENS kit from Addgene [43]. TALENs were designed 
to target the DLEU1 transcription start and stop site 
on chromosome 13q14.3. To examine the validity of 
constructed TALENs pairs in mammalian cells, plasmids 
expressing each TALENs pair were transfected into 
Human embryonic kidney (HEK)293 cells and genomic 
DNA was extracted 24 hours post-transfection. Disrupted 
target sequences caused by non-homologous end joining 
(NHEJ) were confirmed by surveyor mutation detection 
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assay (Supplementary Figure 1) and sequencing analysis 
(data not shown).
Cell culture and transfection
HEK293 and Raji human BL cells were obtained 
from ATCC (Manassas, VA) and maintained as previously 
described [44, 45]. These cell lines were authenticated 
by ATCC, and were provided us within 6 months before 
the use of cells, and cells were passaged for fewer than 
8 weeks of resuscitation in our laboratory. Plasmid 
constructs were transfected into HEK293 and Raji cells 
using Lipofectamine® reagent (Invitrogen) and Amaxa 
Nucleofector™ Kit V (Lonza), respectively according to 
the manufacturer instructions.
Surveyor nuclease assay
Genomic DNA was extracted from cells 
24–48 hours post-transfection using a genomic DNA 
extraction kit (Promega). The measurement of NHEJ - 
mediated mutation was performed using the Surveyor 
endonuclease assay kit (Transgenomic, Inc.) according to 
the manufacturer’s instructions. The PCR primers used 
are as follows: F2, 5′-TCTTGCTTTCCCGACATTT 
TTACG-3′, F4, 5′-CTAGAAGAGCCAACCAACAG-3′, 
and R1, 5′-AGTTGTTCCGAGGCTTAAGTGC GA-3′.
Generation of TALENs mediated DLEU1 
knockdown cell line
Cells were transfected with TALEN expression 
plasmids and genomic DNA was extracted at 48 hours 
post-transfection followed by Surveyor nuclease assay as 
above. Raji cells with DLEU1 gene modification identified 
by NHEJ were seeded into 96 well plates to isolate a 
single clone. Individual colonies were picked, expanded 
and re-genotyped as described above.
Establishment of BL cell line stably 
overexpressing DLEU1
The DLEU1 overexpression construct (GFP-
DLEU1) was generated by cloning the full length DLEU1 
cDNA into pEGFP-N3 vector. GFP-DLEU1 was then 
transfected into 293T or Raji cells. Cells were selected 
under G418 (500 ug/ml) for stable clones and expression 
of GFP-DLEU1 was confirmed by qRT-PCR and Western 
blotting analyses. 
Quantitative reverse-transcriptase PCR (qRT-
PCR)
Total RNA was prepared using TRIzol reagent 
(Invitrogen) according to the manufacturer’s instruction 
and 1 ug of RNA was used for cDNA synthesis using 
qScript™ cDNA Synthesis Kit (Quantas). qRT-PCR was 
performed on the CFX96 Real-time system (Bio-rad) using 
SsoFast™ EvaGreen® Supermix (Bio-rad). Primers used in 
qRT-PCR are provided in Supplementary Table 2. Relative 
quantification (ddCt) of mRNA expression of genes was 
determined by normalizing to the housekeeping gene, 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Western blotting analysis
Western blot analysis was performed as we have 
previously described [44]. Band intensities on SDS-
PAGE gel were measured using ImageJ software program. 
Antibodies specific for GAPDH, phospho-Akt and Akt, 
phospho-IκBα and IκBα and GFP were purchased from 
Cell Signaling Technology and an antibody specific for 
DLEU1 was provided by ProteinTech. Antibodies specific 
for anti-apoptotic genes, Bcl-2, Bcl-xL, and Mcl-1 and 
pro-apoptotic proteins, Bad and Bax were purchased from 
Cell Signaling Technology.
Cell proliferation assay
Prior to cell proliferation measurements, cells were 
treated without or with various doses of RTX (0 – 100 ug/
ml), CTX (0 – 10 mM) alone and in combination. Cells 
(1 × 104) were plated into 48 well plates and then counted every 
24 hrs as previously described [44]. Cell growth was 
determined using the non-radioactive CellTiter 96® Aqueous 
One solution cell proliferation assay (MTS) (Promega) and 
measured by a Multiabel Counter (Perkin Elmer) at OD490. 
Caspase 3/7 assay
Caspase 3/7 activity was directly measured at 48 and 
72 hours after treatment using Caspase-Glo 3/7 Activity 
kit (Promega) according to the manufacturer’s protocol. 
Relative light intensity was measured in each well using 
Clarity Luminescence Microplate Reader (BioTek).
Antibodies and reagents
A chimeric human and mouse anti-CD20 type I 
mAb, Rituximab (RTX), was purchased from Genentech 
Inc. and CTX was purchased from Sigma Aldrich and 
dissolved as a stock solution in PBS.
Gene expression profiling 
Gene expression profiling experiments were 
performed using Affymetrix Human Genome 133 Plus 
2.0 arrays at the Rockefeller University Genomics Facility. 
Two hundred nanograms of total RNA were biotin-labeled 
using Ambion MessageAmp™ Premier RNA Amplification 
Kit (Life Technologies). The fragmented aRNA was 
hybridized to the array as described in the Affymetrix 
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Technical Analysis Manual (Affymetrix). Gene Chips 
were stained with streptavidin-phycoerythrin, and then 
scanned with the Affymetrix GeneChip Scanner 3000 7G. 
Data has been deposited in the NCBI’s Gene Expression 
Omnibus data base (accession number GSE65674). 
Microarray data processing and analysis
Signal intensity was processed using MAS5 
algorithm. The Probe sets that were not tagged as present 
in any samples according to the presence-absence-call 
and control probe sets were discarded. Among 21,437 
surviving probe sets, we identified probe sets whose signal 
ratio between test group average and control group average 
exceeded two-fold as DEG [46] and retained for further 
analyses. We used DAVID (version 6.7) to investigate the 
biological processes and pathways implicated by DEG 
[47]. Specifically, we employed the functional annotation 
clustering utility that clusters functionally related terms 
linked to DEG. We interrogated over-expressed and under-
expressed probe sets separately.
In vivo xenograft models
All experimental animals were γ- irradiated (2.5 Gy) 
1 day before cell transplantation. DLEU1-KD and mock 
control (WT), or GFP-DLEU1 and mock control (GFP) 
were transfected with a firefly luciferase expression 
plasmid (ffluc-zeo, kindly provided by Laurence Cooper 
MD, PhD) into Raji cells followed by zeocin selection 
for stable clones. These selected cells (1 × 106) were then 
subcutaneously injected into four- to six-week-old female 
NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice from 
Jackson laboratory. After verification of tumor burden by 
bioluminescence imaging using the Xenogen IVIS-200 
(Caliper Life Sciences), mice were treated with either PBS 
control (n = 5 per group), or RTX (30 mg/kg, n = 12 per 
group), or CTX (25 mg/kg, n = 12 per group) or RTX 
together with CTX (n = 12 per group) by intraperitoneal 
(i.p) injection at 7 day intervals as we have previously 
described [48]. Tumor progression was monitored at day 
7 and once every week by bioluminescence imaging. 
All mice were housed and maintained under specific 
pathogen-free conditions under protocols (51-2-0913H 
and 59-2-1113H) approved by the Institutional Animal 
Care and Use Committee at New York Medical College.
Statistical analysis
Significant differences between DLEU1-KD vs WT 
or GFP-DLEU1 vs GFP groups (RT-PCR, cell proliferation 
assay, Caspase 3/7 assay and band intensity by Western 
blot) were determined by using one-tailed paired Student’s 
t-test in Microsoft Excel and p-values less than 0.05 were 
considered significant. Error bars are described in the 
Figure legends as ± SD. Survival rates were analyzed by 
the Kaplan-Meier method and differences evaluated by 
log-rank test using the Prism Version 6.0 software.
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